Jorge Becerril
Investments / Public Equity Team at Novo Holdings
Jorge Becerril
Investments / Public Equity Team at Novo Holdings
San Francisco, California
Overview
Work Experience
Partner - Venture Investments / Public Equity Team
2024 - Current
Principal - Venture Investments
2021 - 2024
Executive Director, Corporate Development
2021 - 2021
Senior Director, Corporate Development
2017 - 2021
Source, evaluate, and negotiate in-licensing and M&A transactions in the orphan disease space Lead partner selection and negotiations of agreements for ex-US Oxbryta commercialization
GBT is a clinical-stage biopharmaceutical company developing a therapy for sickle cell disease.
Raised $969,500,000.00 from Cowen Investment Management.
Director, Business Development
2014 - 2017
Source, evaluate, and negotiate in-licensing and M&A transactions in the areas hematology, immunology, oncology, and cardiovascular disease
Portola Pharmaceuticals develops therapeutics for acute and chronic cardiovascular, and autoimmune and inflammatory diseases.
Raised $1,314,100,015.00 from Athyrium Capital Management LP and HealthCare Royalty Partners.
Senior Consultant, Life Sciences Practice
2010 - 2014
Led strategy and investment due diligence engagements for a variety of life sciences clients including startup and large biopharma as well as medtech, diagnostics, research tools and private equity firms
Postdoctoral Associate
2009 - 2010
Postdoctoral Researcher
2007 - 2008
Developed chemical methodologies to create libraries of structurally complex molecules for biological screening